US2007172452A1PendingUtilityA1
Methods for treating viral infection using il-28 and il-29
Est. expiryOct 23, 2022(expired)· nominal 20-yr term from priority
A61P 31/20A61P 7/00A61P 31/14A61P 31/12A61K 38/20A61K 47/60A61K 38/21A61P 1/16C07K 14/54Y02A50/30
64
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof do not exhibit some of the antiproliferative activity on hematopoietic cells that is observed with interferon treatment. Without the immunosuppressive effects accompanying interferon treatment, IL-28A, IL-28B, and IL-29 will be useful in treating immunocompromised patients for viral infections.
Claims
exact text as granted — not AI-modified1 . A method of treating a viral infection comprising administering to an immunocompromised mammal with a hepatitis infection a therapeutically effective amount of a polypeptide comprising amino acid residues 1-175 of SEQ ID NO:28, wherein after administration of the polypeptide the hepatitis infection is reduced.
2 . The method of claim 1 wherein the polypeptide is conjugated to a polyalkyl oxide moiety.
3 . The method of claim 2 wherein the polyalkyl oxide moiety is a polyethylene glycol.
4 . The method of claim 1 wherein the hepatitis infection is a hepatitis B infection.
5 . The method of claim 1 wherein the hepatitis infection is a hepatitis C infection.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.